Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of macitentan 75 mg versus macitentan 10 mg in pulmonary arterial hypertension with open-label extension
CTR20211698Phase 3Active
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of macitentan in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Started Jan 2022; status: active.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on CTR20211698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211698.